Literature DB >> 9794488

Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells.

N J Horwood1, J Elliott, T J Martin, M T Gillespie.   

Abstract

The osteoclastogenic factor of osteoblastic origin has recently been elucidated as a novel Tumor Necrosis Factor (TNF)-ligand family member, termed osteoclast differentiation factor (ODF). Using a semiquantitative RT-PCR approach, we sought to determine the mRNA expression of ODF and its decoy receptor, osteoprotegerin (OPG), in a selection of osteoblastic cell lines and in response to three factors representative of different signal transduction pathways, vitamin D receptor, protein kinase A or gp130. Each osteotropic agent, either 1,25-(OH)2D3, PTH or IL-11, promoted an increase in the ratio of ODF:OPG, with maximal stimulation occurring at 24 h, 4 h, and 8 h, respectively, and furthermore each was shown to act in a dose-dependent manner. This report establishes that osteoblastic cell lines incapable of supporting osteoclast formation have markedly reduced ODF expression and also illustrates the importance of the relative abundance of ODF compared with the levels of OPG for the induction of osteoclastogenesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9794488     DOI: 10.1210/endo.139.11.6433

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  64 in total

Review 1.  Osteoprotegerin.

Authors:  U Feige
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

2.  Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation.

Authors:  L Huang; J Xu; D J Wood; M H Zheng
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

Review 3.  Paget disease of bone.

Authors:  G David Roodman; Jolene J Windle
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

4.  Differential regulation of osteoblast activity by Th cell subsets mediated by parathyroid hormone and IFN-gamma.

Authors:  Nathan Young; Natallia Mikhalkevich; Ying Yan; Di Chen; Wei-ping Zheng
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

Review 5.  The molecular mechanism behind bone remodelling: a review.

Authors:  Peter Proff; Piero Römer
Journal:  Clin Oral Investig       Date:  2009-03-25       Impact factor: 3.573

Review 6.  Historically significant events in the discovery of RANK/RANKL/OPG.

Authors:  T John Martin
Journal:  World J Orthop       Date:  2013-10-18

7.  High bone resorption in adult aging transgenic mice overexpressing cbfa1/runx2 in cells of the osteoblastic lineage.

Authors:  Valérie Geoffroy; Michaela Kneissel; Brigitte Fournier; Alan Boyde; Patrick Matthias
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

8.  Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.

Authors:  Adel Ersek; Ke Xu; Aristotelis Antonopoulos; Terry D Butters; Ana Espirito Santo; Youridies Vattakuzhi; Lynn M Williams; Katerina Goudevenou; Lynett Danks; Andrew Freidin; Emmanouil Spanoudakis; Simon Parry; Maria Papaioannou; Evdoxia Hatjiharissi; Aristeidis Chaidos; Dominic S Alonzi; Gabriele Twigg; Ming Hu; Raymond A Dwek; Stuart M Haslam; Irene Roberts; Anne Dell; Amin Rahemtulla; Nicole J Horwood; Anastasios Karadimitris
Journal:  J Clin Invest       Date:  2015-04-27       Impact factor: 14.808

9.  The differential expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappaB ligand (RANKL) in human osteoarthritic subchondral bone osteoblasts is an indicator of the metabolic state of these disease cells.

Authors:  S Kwan Tat; J-P Pelletier; D Lajeunesse; H Fahmi; M Lavigne; J Martel-Pelletier
Journal:  Clin Exp Rheumatol       Date:  2008 Mar-Apr       Impact factor: 4.473

Review 10.  Non-Canonical (RANKL-Independent) Pathways of Osteoclast Differentiation and Their Role in Musculoskeletal Diseases.

Authors:  A Sabokbar; D J Mahoney; F Hemingway; N A Athanasou
Journal:  Clin Rev Allergy Immunol       Date:  2016-08       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.